Related Experiment Video
Updated: Jan 13, 2026
08:21
Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery
Published on: June 28, 2019
7.3K
Distinct membrane binding properties of the two non-visual arrestins
Thomas D Killeen1, Katelyn Tepper2, Kyle W Miller2
1Department of Physics, University of Wisconsin-Milwaukee, Milwaukee, WI, USA.
Communications Biology
|January 7, 2026
Summary
Arrestin-2 and arrestin-3 show distinct membrane interactions, with arrestin-2 binding PI(4,5)P2-rich membranes more strongly. These differences in arrestin subtypes are crucial for G protein-coupled receptor (GPCR) signaling and activation.
Area of Science:
- Molecular and Cellular Biology
- Biophysics
- Pharmacology
Background:
- Arrestin activation and G protein-coupled receptor (GPCR) binding are regulated by membrane interactions.
- Non-visual arrestin subtypes, arrestin-2 and arrestin-3, play critical roles in cellular signaling pathways.
Purpose of the Study:
- To systematically compare the membrane-binding properties of arrestin-2 and arrestin-3.
- To elucidate the distinct mechanisms of arrestin activation and membrane engagement.
Main Methods:
- In vitro biophysical techniques.
- Cell-based fluorescence intensity fluctuation analysis.
- Live-cell tracking of arrestin dynamics.
Main Results:
- Arrestin-2 exhibits higher affinity for PI(4,5)P2-enriched membranes than arrestin-3, primarily engaging via its C-edge.
- Upon activation, arrestin-2 shifts to using its finger loop for membrane interaction, unlike arrestin-3.
- Membranes synergistically promote arrestin recruitment and activation with phosphorylated GPCRs.
Conclusions:
- Distinct membrane interaction modes of arrestin-2 and arrestin-3 are revealed.
- These findings provide mechanistic insights into arrestin activation and GPCR signaling.
- Understanding arrestin-membrane interplay is key for drug discovery targeting GPCRs.
Related Concept Videos
01:17Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
2.7K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
2.7K
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
898
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
898
01:15Cholinergic Receptors: Nicotinic
5.3K
Nicotinic receptors are ligand-gated ion channels that are activated by acetylcholine and nicotine. Upon activation, they cause a rapid increase in the permeability of cells to K+, Na+, and Ca2+, followed by depolarization and excitation. They are in the autonomic ganglia, skeletal neuromuscular junction, CNS, and adrenal medulla.
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...
5.3K
01:31Adrenergic Receptors: ɑ Subtype
2.7K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
2.7K
01:26Adrenergic Receptors: β Subtype
3.4K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
3.4K
01:27Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
884
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
884